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Abstract
Quantitative detection of human cytomegalovirus (HCMV) DNA on whole blood is currently the 
primary choice for virological monitoring in transplant patients and for determining the appropriate 
antiviral  strategy,  however  specific  issues of variability remain in terms of extraction  methods, 
amplification efficiency,  and variability.  This study compared the performance characteristics of 
two nucleic acid extraction and testing systems for HCMV-DNA quantitation, the artus® CMV QS-
RGQ kit, associated with a fully automated DNA extraction and assay set up by Qiagen (system 1) 
and the Q-CMV Real Time Complete kit by Nanogen, associated with a semiautomated nucleic 
acid extraction system by Biomérieux (system 2) in 189 specimens from transplant patients and 10 
from 2012 HCMV Quality Control for Molecular Diagnostics (QCMD). The two systems exhibited 
a 80.4% concordance. Differences between the two systems were within ±1 log10 copies/ml of the 
averaged log10 results for 88.9% of the tested specimens. For all qualitatively discordant specimens, 
mean viral load was ≤3 log10 copies/ml. Considering viral load measurement, system 1 gave earlier 
positives that system 2, with a 14.8% of specimens resulted positive at low viral loads with system 
1 and negative with system 2. In QCMD specimens, difference was below 0.7 log10 copies/ml for 
both the systems. 
In  conclusion,  the  two  systems  provided  reliable  and  comparable  results.  Some  specific 
performance characteristic and automation could be taken into account in terms of less hands of 
time, fewer errors and reliability.  
Keywords:  human  cytomegalovirus;  nucleic  acid;  extraction;  quantitative  PCR;  efficiency; 
variability 
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1. Introduction
Human cytomegalovirus (HCMV) is an important viral pathogen in both solid organ transplant and 
hematopoietic stem cell transplant recipients in terms of morbidity and mortality. The frequency of 
HCMV infection and disease in the post-transplant period depends on the interaction of factors 
related to the host, virus and transplantation practices, with HCMV serostatus being considered the 
single most important predictor of disease. Among virus-related factors, the development of HCMV 
disease has been directly related to the degree of viral replication. Management of HCMV disease 
varies  considerably  among  transplant  centres.  A  panel  of  experts  on  HCMV  and  solid 
organ/hematopoietic stem cell transplant was convened to develop international guidelines for the 
management of HCMV including diagnostics, immunology, prevention, and treatment (Kotton et 
al., 2010; Zaia et al.,  2009).  Currently,  the diagnosis of HCMV replication and disease in solid 
organ and  hematopoietic stem cell transplant  patients can be performed using different methods, 
including histopathological analysis, quantitative pp65-antigenaemia in peripheral blood leukocytes 
and quantitative nucleic acid testing. Quantitative detection of HCMV-DNAemia by real-time PCR 
is currently the primary choice for virological monitoring of HCMV infection in transplant patients; 
in fact, HCMV-DNA quantitation provides sensitive and specific data for viral detection as well as 
monitoring the development and course of infection, thus being fundamental for determining the 
appropriate  antiviral  strategy.  A  relevant  issue  in  HCMV  routine  diagnostics  is  the  interassay 
quantitation variability (Hirsch et al., 2013; Lilleri et al., 2009), possibly complicating the clinical 
management  and  therapeutic  decision  process  in  patients  evaluated  in  different  laboratories. 
Recently, the first World Health organization  international standard for HCMV quantitative nucleic 
acid  amplification-based  assays  has  been  made  available  (Freyer  et  al.,  2010).  Although  the 
availability of the international standard should contribute to improve interassay agreement, specific 
issues  of  variability  remain  in  terms  of  extraction  methods  and  DNA  elution,  amplification 
efficiency, and operator-dependent variability (Hirsch et al., 2013; Kraft et al., 2012).  
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The aim of this study was to assess the performance characteristics of two nucleic acid extraction 
and  testing  systems  for  HCMV-DNA  quantitation,  the  artus®  CMV  QS-RGQ  kit  by  Qiagen, 
(Hilden, Germany) associated with a fully automated DNA extraction and assay set up by Qiagen 
and the Q-CMV Real Time Complete kit by Nanogen, Elitech Group (Milan, Italy) associated with 
a semiautomated nucleic  acid extraction system by Biomérieux (Marcy l’Etoile,  France).  Using 
whole blood clinical specimens from transplant patients, the two systems were compared and the 
potential clinical implications were evaluated.
4
69
70
71
72
73
74
75
7
2. Materials and methods 
2.1. Clinical specimens 
One-hundred-fifty-six patients referred to the Virology Unit of the Azienda Ospedaliera Città della 
Salute e della Scienza di Torino, Italy, for routine HCMV load testing (90 solid organ transplant 
recipients and 66 hematopoietic stem cell transplant recipients) were included in the study. One-
hundred-eighty-nine specimens of whole blood (EDTA tubes) were collected between January and 
June  2012.  Ten  HCMV quality  control  specimens  (Quality  Control  for  Molecular  Diagnostics 
-QCMD- 2012 CMV panel) were also processed.
2.2 Study design
Two nucleic acid extraction and testing systems for HCMV-DNA were evaluated: the artus® CMV 
QS-RGQ  kit  (Qiagen),  a  commercial  real-time  PCR for  HCMV-DNA  associated  with  a  fully 
automated DNA extraction from whole blood (Qiasymphony, Qiagen) and automated assay set up – 
system 1  -  and the  Q-CMV Real  Time  Complete  kit,  a  commercial  real-time  PCR (Nanogen, 
Elitech Group) associated with a semiautomated nucleic acid extraction system from whole blood 
(Easymag, Biomérieux) and manual assay set up  – system 2. Currently, the Q-CMV Real Time 
Complete kit, validated for EasyMAG extraction system by the manufacturer, is the routinely used 
method. 
For system 1, nucleic acid extraction was performed according to the manufacturer’s instructions; 
nucleic acid was purified with the QIAsymphony DNA Mini kit on the QIAsymphony instrument 
(Qiagen). Two-hundred microliters of whole blood were concentrated into a 60-µl eluate, and a 20 
μl aliquot was used for the PCR on the real-time PCR cycler Rotor-Gene Q (Qiagen). The artus® 
CMV QS-RGQ kit targets the major immediate early (MIE) CMV gene. The reaction volume was 
50-µl  (20  µl  of  eluate  plus  30  µl  of  master  mix).  Analytical  sensitivity,  as  reported  by  the 
manufacturer, considering purification from whole blood (using the QIAsymphony DNA Mini kit) 
and the use of artus® CMV QS-RGQ kit on the Rotor-Gene Q, is 164.55 copies/ml.
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For  system  2,  nucleic  acid  was  purified  with  the  NucliSENS®  EasyMAG®  instrument 
(Biomérieux),  using  the  NucliSENS  ®  Nucleic  Acid  Extraction  Reagents,  according  to  the 
manufacturer’s instructions.  
One-hundred microliters of whole blood were concentrated into a 50-µl eluate, and a 5µl aliquot 
was  used  for  PCR assay on the  7500 Real-Time PCR System (Applied  Biosystems,  Cheshire,  
United Kingdom). The Q-CMV Real Time Complete kit manufactured for Cepheid by Nanogen 
Advanced  Diagnostics  S.r.L.  is  specific  for  the  exon  4  region  of  the  CMV MIE gene  (major 
immediate early HCMVUL123). The reaction volume was 25 µl (5 µl of eluate plus 20 µl of master 
mix).  The limit  of  detection  of  the  Q-CMV real  time kit  is  158 copies/ml,  as  reported  by the 
manufacturer. The main technical features of the two systems are summarized in Table 1.
2.3. Statistical analysis 
The correlation between the two systems was determined by linear regression analysis and mean 
differences in quantitation for averaged logs by the Bland-Altman plot. Only viral loads positive by 
both assays were represented on the Bland-Altman graphs. Differences were considered significant 
for p value <0.05. 
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3. Results 
The performance of the two systems was assessed and compared on 189 whole blood specimens 
from 156 transplant  recipients  undergoing  routine  testing  in  the  first  year  post-transplantation. 
System 1 and system 2 detected HCMV-DNA in 118 and 99 samples, respectively, with a 80.4% 
concordance. In particular, 62/189 (32.8%) were concordantly negative by both systems; 90/189 
(47.6%) concordantly positive; 28/189 (14.8%) positive by system 1 and negative by system 2; and 
9/189 (4.8%) positive by system 2 and negative by system 1 (Table 2). For the 90 specimens that 
were positive by both tests, the population mean (SD) was 4.25 (4.58) log10 copies/ml with system 1 
and  4.06  (4.29)  log10 copies/ml  with  system  2.  For  all  the  specimens  that  were  qualitatively 
discordant (by one of the two systems), mean viral load was lower or equal to 3 log10 copies/ml. 
By referring to the 90 specimens that were concordantly positive, the correlation value between the 
two systems was r = 0.597 (Fig. 1). Bland-Altman analysis showed that differences between the two 
systems  were  within  ± 1  log10 copies/ml  of  the  averaged log10 results  for  88.9% of  the  tested 
specimens (Fig. 2). Table 3 depicts the HCMV load results for the 10 specimens from the QCMD 
2012 HCMV proficiency panel.  The sample for which a negative result was expected was found 
negative by the two systems, whereas for the positive specimens the difference was below 0.7 log10 
copies/ml for both the systems (mean Δlog10 0.1566 for system 1 and 0.2288 for system 2). 
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4. Discussion 
The automation of nucleic acid extraction and availability of commercial real-time quantitative PCR 
assays  have  the  potential  to  improve  the  agreement  and  clinical  usefulness  of  HCMV-DNA 
measurement in routine transplant settings, thus promoting standardization across laboratories and 
enabling correlation with clinical study results. 
In the present study, the HCMV –DNA load results obtained by two nucleic acid extraction and 
testing systems have been compared. Overall, both systems appear as reliable and user-friendly for 
monitoring HCMV-DNAemia in transplant recipients. 
The two systems  exhibited  an  overall  concordance  of  80.4% in  qualitative  terms.  Considering 
specimens  that  were  positive  by  both  the  systems,  the  mean  viral  load  differs  of  0.19  log10 
copies/ml. On the other hand, when considering specimens that were qualitatively discordant, mean 
viral load was lower or equal to 3 log10 copies/ml. 
Considering viral load measurement, system 1 gave earlier positives that system 2, as evidenced by 
the  evaluation  of  frequency  distribution  for  different  log  of  viral  load  (not  shown),  with 
approximately 15% of specimens resulted positive at low viral loads with system 1 and negative 
with system 2. This is likely to be attributable to the fact that system 1 employs more blood derived  
material  in  comparison  to  system  2,  thus  improving  the  recovery  ability  in  the  nucleic  acid 
purification phase. This should be taken into account in the monitoring of transplant recipients as it 
could be useful for prompt identification of patients at risk and could allow for rechecking on a 
subsequent specimen within a short period. 
Monitoring of HCMV-DNAemia has become critical for early identification of viral reactivation 
with the aim of reducing the occurrence of systemic and/or organ disease in the post-transplant 
setting and of evaluating the response to antiviral therapy. Although both antiviral prophylaxis and 
pre-emptive therapy are useful strategies to prevent the occurrence of HCMV disease, the potential 
exposure to adverse events associated with prolonged antiviral drug administration has limited the 
utility of a universal prophylaxis strategy, thus suggesting its adoption only in high risk patients,  
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such as HCMV-seropositive donor/HCMV-seronegative recipients. On the other hand, viral load 
monitoring  for  guiding  pre-emptive  therapy is  critical.  The  adoption  of  a  pre-emptive  strategy 
appears  advantageous  in  terms  of  number  of  treated  patients,  appropriateness  of  antiviral 
administration  and duration of therapy,  costs,  risks of onset  of drug adverse events,  as well  as 
emergence of drug-resistant strains. 
By using the Bland-Altman analysis, differences between the two systems were within ± 1 log10 
copies/ml of the averaged log10 results for almost 89% of the tested specimens. The occurrence of 
constant and variable quantitation differences among nucleic acid assays underlines the usefulness 
of a general quantitative standardization, that could also allow for a better evaluation of specific 
differences only related to different technical performances of the assays. 
From an organizational point of view, system 1, being a full-automated system, provides benefits 
over a semi-automated system, in terms of less hands of time, fewer errors and reliability, that are 
relevant factors in a high-routine laboratory.   It is to note that the present study compared two 
testing  systems  with  two  different  extraction  methods,  therefore  it  is  not  known  whether  the 
differences came from the nucleic acid purification techniques or from the two HCMV tests or 
probably  both;  further  studies  including  cross-test  of  both  extraction  methods  with  both  PCR 
systems could help to clarify this. Further data on a larger number of specimens and evaluation of 
clinical  management  based  on HCMV-DNAemia  results  will  allow for  better  definition  of  the 
performance characteristics and clinical validation. 
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Table 1 
Performance characteristics of the two nucleic acid extraction and testing systems.
*Technical specifications as indicated in the manufacturer’s report.
11
Features System 1 System 2
Target MIE MIE
Extracted DNA volume in PCR reaction (μl) 20 5
Final volume (μl) in assay 50 25
No, type of quantitation standards 4, plasmid 4, plasmid
Analytical sensitivity* 164,55 copies/ml 158 copies/ml
Specificity* 100% 90%
Linear range* 1x103-5x107 
copies/ml
20-1x106- 
copies/reaction
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Table 2 
Detection of HCMV-DNA obtained by systems 1 and 2 on 189 whole blood specimens.
System 1
POS NEG
System 2
POS 90 (47.6%) 9 (4.8%) TOT 99
NEG 28 (14.8%) 62 (32.8%)
TOT 118
Table 3 
System 1 and 2 variability within the QCMD 2012 HCMV proficiency panel.
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Samples System 1 results
log10 (copies/ml)
System 2 results
log10 (copies/ml)
QCMD results
log10 (copies/ml)
 Difference system 1 / 
QCMD log10 (copies/ml)
Difference system 2 /  
QCMD log10 (copies/ml)
CMV12-01 4.36 4.46 4.30 0.06 0.16
CMV12-02 3.89 3.86 3.74 0.15 0.12
CMV12-03 2.30 2.14 2.24 0.06 -0.10
CMV12-04 1.43 1.47 2.07 -0.64 -0.60
CMV12-05 2.99 3.40 2.90 0.09 0.50
CMV12-06 3.33 3.51 3.30 0.03 0.21
CMV12-07 3.50 3.50 3.32 0.18 0.18
CMV12-08 negative negative negative / /
CMV12-09 3.62 3.82 3.67 -0.05 0.15
CMV12-10 2.88 2.69 2.73 0.15 -0.04
13
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Fig. 1. Linear regression plot for log values of system 1 and system 2, by referring to the 90 double 
positive samples.
Fig. 2. Mean differences in HCMV-DNA quantitation of 90 positive specimens with system 1 and 2 
by Bland-Altman analysis.
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Figure 1
Log10 CMV-DNA copies/ml by system 2
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